Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention

The use of hydroxychloroquine for COVID-19 treatment and prevention should be restricted in both out- and inpatient settings due to the lack of evidence for effectiveness and unfavorable safety profile

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2

The routine use of bromhexine to prevent infection SARS-CoV-2 is not recommended. The use of bromhexine is possible in clinical trials

Dexamethasone use in patients with COVID-19

Dexamethasone may be used for mortality reduction in patients with severe COVID-1

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab

No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, when interleukin-6 blockers (tocilizumab, sarilumab) are unavailable

Could canakinumab be used for COVID-19?

Use of canakinumab in patients with COVID-19 is currently lacking proper evidence base, and should not be recommended outside of clinical trials

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19

Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients with COVID-19 due to the lack of clinical trial results, significant potential interactions

Current and future use of remdesivir in patients with COVID-19

There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictory

Is it possible to use riamilovir to prevent infection and treat COVID-19?

Routine clinical use of riamilovir in COVID-19 is not recommended. The use of riamilovir is possible in clinical trials

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?

Hyaluronidase is currently not included into Russian or foreign guidelines on the treatment of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported by evidence of clinical effectiveness. Hyaluronidase can only be used for COVID-19 within clinical trials

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy

There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium aminodihydrophthalazindione at COVID-19 have not been found. The use of sodium aminodihydrophthalazindione in the treatment of COVID-19 is possible only in clinical trials